extent
intraspeci
divers
bacteri
popul
underlin
recent
studi
focus
wholegenomesequ
comparison
eight
streptococcu
agalactia
result
reveal
genom
whole
bacteri
speci
consist
core
gene
dispens
gene
partli
share
might
much
larger
genom
singl
isol
wholegenom
compar
genom
potenti
shed
light
mechan
genom
evolut
includ
horizont
gene
transfer
recombin
gene
duplic
gene
loss
shape
structur
microbi
popul
insight
gain
analys
core
dispens
gene
use
develop
better
treatment
effici
broadli
applic
moreov
compar
genom
make
possibl
us
map
time
genetransf
event
evolutionari
histori
bacteria
onto
evolutionari
histori
host
might
reveal
interact
key
genetransf
event
evolut
behaviour
demograph
chang
host
lead
emerg
novel
pathogen
one
success
method
provid
protect
pathogen
vaccin
treatment
origin
reli
process
biolog
agent
balanc
reduc
virul
immunogen
convent
vaccin
develop
pathogen
strain
grown
sequenti
passag
vitro
develop
live
attenu
kill
strain
harmless
host
retain
abil
trigger
protect
immun
respons
altern
approach
involv
use
antigen
basi
subunit
vaccin
although
promis
convent
vaccin
approach
applic
pathogen
grown
vitro
exampl
hepat
b
c
virus
pathogen
immunodomin
cellular
compon
resembl
compon
human
tissu
exampl
serogroup
b
meningococcu
menb
moreov
convent
vaccin
approach
time
consum
year
identifi
exploit
antigen
highli
express
immunogen
diseas
recent
differ
method
use
bottomup
rather
topdown
genom
instead
cellular
approach
success
appli
develop
vaccin
pathogen
previous
recalcitr
develop
requir
new
process
genom
sequenc
sequenc
target
pathogen
genom
sequenc
use
input
materi
silico
algorithm
make
predict
put
antigen
like
success
vaccin
candid
approach
use
genom
sequenc
rather
cell
start
materi
name
revers
revers
vaccinolog
fast
year
depend
avail
highthroughput
screen
system
identifi
virtual
potenti
antigen
irrespect
concentr
time
express
immunogen
use
pathogen
includ
grown
vitro
howev
methodolog
current
use
develop
vaccin
base
nonproteincod
antigen
lipopolysaccharid
tabl
two
version
revers
vaccinolog
classic
revers
vaccinolog
use
singl
genom
sequenc
make
predict
put
vaccin
candid
compar
pangenom
revers
vaccinolog
compar
genom
sever
close
distantli
relat
strain
revers
vaccinolog
recent
success
appli
develop
univers
vaccin
group
b
gb
vaccin
candid
revers
vaccinolog
routin
approach
also
appli
lifethreaten
pathogen
includ
staphylococci
two
version
revers
vaccinolog
classic
revers
vaccinolog
use
singl
genom
make
predict
put
vaccin
candid
compar
pangenom
revers
vaccinolog
compar
genom
sever
close
distantli
relat
compar
revers
vaccinolog
gener
use
develop
univers
rather
strain
serovarspecif
vaccin
biggest
advantag
revers
vaccinolog
speed
probabl
vital
import
tackl
rapidli
emerg
lifethreaten
diseas
exampl
recent
emerg
sever
acut
respiratori
syndrom
sar
genom
sequenc
respons
coronaviru
rapidli
made
avail
less
month
first
suggest
type
viru
might
respons
diseas
enabl
rapid
identif
put
vaccin
gb
one
common
caus
agent
lifethreaten
infect
includ
mening
pneumonia
septicaemia
newborn
babi
develop
world
gb
commens
gramposit
bacterium
carri
onethird
healthi
individu
occasion
caus
diseas
vaccin
develop
use
revers
vaccinolog
gb
promis
defenc
neonat
killer
although
conjug
vaccin
gb
serotyp
develop
test
provid
protect
homolog
serotyp
necessarili
serotyp
differ
geograph
reflect
analysi
numer
gb
genom
suggest
pangenom
open
even
hundr
gb
genom
sequenc
pangenom
never
fulli
therefor
compar
reversevaccinolog
approach
crucial
develop
univers
gb
vaccin
maion
et
compar
genom
sequenc
gb
isol
predict
set
core
gene
share
strain
dispens
gene
pool
gene
limit
phylogenet
distribut
gene
pool
independ
use
input
silico
method
predict
core
dispens
gene
encod
put
surfaceexpos
protein
half
predict
protein
success
express
escherichia
coli
purifi
use
immun
femal
mice
reversevaccinolog
approach
yield
four
put
vaccin
candid
significantli
increas
surviv
rate
challeng
neonat
mice
import
contribut
studi
fact
although
none
four
antigen
repres
univers
vaccin
owe
either
limit
phylogenet
distribut
correspond
gene
minim
surfac
access
antigen
combin
four
antigen
provid
protect
nine
major
gb
serotyp
also
impli
convent
vaccin
develop
even
classic
reversevaccinolog
approach
use
singl
genom
sequenc
would
probabl
fail
identifi
four
antigen
neisseria
meningitidi
gramneg
betaproteobacterium
colon
mucos
surfac
nasopharynx
healthi
individu
anoth
commens
occasion
invad
blood
cerebrospin
fluid
caus
septicaemia
mening
five
pathogen
n
meningitidi
serogroup
name
b
c
classifi
accord
capsular
polysaccharid
cpss
polysaccharid
conjug
vaccin
avail
serotyp
except
b
menb
respons
onethird
meningococc
diseas
unit
state
case
europ
two
main
reason
success
menb
vaccin
develop
far
limit
convent
vaccin
develop
first
cp
produc
success
vaccin
four
serotyp
chemic
ident
menb
selfantigen
present
sever
human
tissu
second
major
proteinbas
antigen
show
high
sequenc
variabl
offer
protect
immun
homolog
strain
pizza
et
first
success
implement
concept
revers
vaccinolog
use
complet
genom
sequenc
virul
menb
strain
input
predict
algorithm
identif
put
vaccin
candid
less
year
author
predict
put
surfaceexpos
protein
half
clone
express
e
coli
purifi
use
immun
mice
quarter
protein
novel
antigen
expos
surfac
menb
cell
almost
onethird
protein
induc
bactericid
antibodi
respons
novelti
approach
identifi
antigen
well
conserv
sequenc
level
ideal
develop
vaccin
offer
protect
wide
rang
homolog
even
heterolog
menb
strain
revers
vaccinolog
promis
method
highthroughput
discoveri
put
populationwid
rather
strain
serotypespecif
vaccin
candid
potenti
mirror
variabl
dynam
divers
entir
microbi
popul
next
big
challeng
devis
effici
algorithm
pipelin
standard
approach
make
highthroughput
